Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 140 of the 141 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia. PARTICIPANTS: The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines. CONCLUSIONS: Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have reported that 44-62% of cases experience a reversal of hypogonadism, usually within 6 months after starting treatment (225,226).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [226]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Persistently elevated prolactin levels can indicate the presence of pituitary tumors, such as prolactinomas”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“development and implementation of evidence-based guidelines (1).”
Fernandez, A., Karavitaki, N., & Wass, J. A. H. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03667.x · Cited by 1,115
Self-citationHigh Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
Daly, A. F., Rixhon, M., Adam, C., Dempegioti, A., Tichomirowa, M. A., & Beckers, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1668 · Cited by 1,025
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Self-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Casanueva, F. F., Molitch, M. E., Schlechte, J. A., Abs, R., Bonert, V., Bronstein, M. D., Brue, T., Cappabianca, P., Colao, A., Fahlbusch, R., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02562.x · Cited by 829
Self-citationAdvances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
A Radioimmunoassay for Human Prolactin
Hwang, P., Guyda, H., & Friesen, H. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.8.1902 · Cited by 752 · cited 2×
“1970 permitted development of RIAs (4, 5), which en-”
Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., & Scanlon, M. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311403 · Cited by 699
Cited by
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Diagnosis and Treatment of Pituitary Adenomas: A Review
Molitch, M. E. (2017) · JAMA · doi:10.1001/jama.2016.19699 · Cited by 933
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Self-citationEvaluation and Management of Testosterone Deficiency: AUA Guideline
Mulhall, J. P., Trost, L. W., Brannigan, R. E., Kurtz, E. G., Redmon, J. B., Chiles, K. A., Lightner, D. J., Miner, M. M., Murad, M. H., Nelson, C. J., et al. (2018) · Journal of Urology · doi:10.1016/j.juro.2018.03.115 · Cited by 766
Pituitary-Tumor Endocrinopathies
Melmed, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1810772 · Cited by 604
Self-citationRaverot, G., Burman, P., McCormack, A., Heaney, A., Petersenn, S., Popovic, V., Trouillas, J., Dekkers, O. M., & _, _. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0796 · Cited by 595
Micko, A. S. G., Wöhrer, A., Wolfsberger, S., & Knosp, E. (2015) · Journal of Neurosurgery · doi:10.3171/2014.12.jns141083 · Cited by 577
“We used the most recent consensus statements 5,6, 25,53 to define ER.”
MethodPetersenn, S., Fleseriu, M., Casanueva, F. F., Giustina, A., Biermasz, N., Biller, B. M. K., Bronstein, M., Chanson, P., Fukuoka, H., Gadelha, M., et al. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00886-5 · Cited by 411
Self-citationDiagnosis and treatment of infertility in men: AUA/ASRM guideline part I
Schlegel, P. N., Sigman, M., Collura, B., De Jonge, C. J., Eisenberg, M. L., Lamb, D. J., Mulhall, J. P., Niederberger, C., Sandlow, J. I., Sokol, R. Z., et al. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.11.015 · Cited by 373
Beckers, A., Aaltonen, L. A., Daly, A. F., & Karhu, A. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1013 · Cited by 360
Roelfsema, F., Biermasz, N. R., & Pereira, A. M. (2012) · Pituitary · doi:10.1007/s11102-011-0347-7 · Cited by 346
Diagnosis and Management of Pituitary Adenomas: A Review
Tritos, N. A., & Miller, K. K. (2023) · JAMA · doi:10.1001/jama.2023.5444 · Cited by 331
New insights in prolactin: pathological implications
Bernard, V., Young, J., Chanson, P., & Binart, N. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.36 · Cited by 246
The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new
Chanson, P., & Maiter, D. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.101290 · Cited by 237
Clayton, A. H., Goldstein, I., Kim, N. N., Althof, S. E., Faubion, S. S., Faught, B. M., Parish, S. J., Simon, J. A., Vignozzi, L., Christiansen, K., et al. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.11.002 · Cited by 226
“In addition, drugs that may elevate prolactin levels and, in part, decrease sexual desire include antipsychotics and others.(38,108) We conclude that CHCs may be associated with HSDD in some women, and thus, change of medication may improve desire [LoE 2].”
BackgroundPhysiological Aspects of Female Fertility: Role of the Environment, Modern Lifestyle, and Genetics
Hart, R. J. (2016) · Physiological Reviews · doi:10.1152/physrev.00023.2015 · Cited by 228
Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients
Vroonen, L., Jaffrain-Rea, M.-L., Petrossians, P., Tamagno, G., Chanson, P., Vilar, L., Borson-Chazot, F., Naves, L. A., Brue, T., Gatta, B., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0236 · Cited by 209
THERAPY OF ENDOCRINE DISEASE: The challenges in managing giant prolactinomas
Maiter, D., & Delgrange, E. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0013 · Cited by 197
The hormonal control of ejaculation
Corona, G., Jannini, E. A., Vignozzi, L., Rastrelli, G., & Maggi, M. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.147 · Cited by 187
Endocrine disorders & female infertility
Unuane, D., Tournaye, H., Velkeniers, B., & Poppe, K. (2011) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.08.001 · Cited by 186
Diagnosis and treatment of infertility in men: AUA/ASRM guideline part II
Schlegel, P. N., Sigman, M., Collura, B., De Jonge, C. J., Eisenberg, M. L., Lamb, D. J., Mulhall, J. P., Niederberger, C., Sandlow, J. I., Sokol, R. Z., et al. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.11.016 · Cited by 183
“Treatment depends on the etiology of the hyperprolactinemia (15).”
BackgroundMazziotti, G., Frara, S., & Giustina, A. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00005 · Cited by 181
Management of Dopamine Agonist-Resistant Prolactinoma
Maiter, D. (2019) · Neuroendocrinology · doi:10.1159/000495775 · Cited by 180
Pituitary adenomas: an overview.
Lake, M. G., Krook, L. S., & Cruz, S. V. (2013) · PubMed · Cited by 193
Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management
Esposito, D., Olsson, D. S., Ragnarsson, O., Buchfelder, M., Skoglund, T., & Johannsson, G. (2019) · Pituitary · doi:10.1007/s11102-019-00960-0 · Cited by 177
Management of hormone-secreting pituitary adenomas
Mehta, G. U., & Lonser, R. R. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now130 · Cited by 169
ENDOCRINOLOGY IN PREGNANCY: Management of the pregnant patient with a prolactinoma
Molitch, M. E. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0848 · Cited by 170
Primeau, V., Raftopoulos, C., & Maiter, D. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1000 · Cited by 169
“In patients with preoperative DA resistance treated again after surgery, there was a significant reduction of prolactin levels postoperatively (26 [6-687] ng/ml) vs.”
BackgroundManagement of medically refractory prolactinoma
Molitch, M. E. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1270-8 · Cited by 165
Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia
Vilar, L., Vilar, C. F., Lyra, R., & Freitas, M. D. C. (2019) · Neuroendocrinology · doi:10.1159/000499694 · Cited by 159
de Laat, J. M., Dekkers, O. M., Pieterman, C. R. C., Kluijfhout, W. P., Hermus, A. R., Pereira, A. M., van der Horst-Schrivers, A. N., Drent, M. L., Bisschop, P. H., Havekes, B., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2015 · Cited by 160
Case Report: Induced Lactation in a Transgender Woman
Reisman, T., & Goldstein, Z. G. (2018) · Transgender Health · doi:10.1089/trgh.2017.0044 · Cited by 149
Treatment of hyperprolactinemia: a systematic review and meta-analysis
Wang, A. T., Mullan, R. J., Lane, M. A., Hazem, A., Prasad, C., Gathaiya, N. W., Fernández-Balsells, M., Bagatto, A., Yglesias, F. C., Carey, J., et al. (2012) · Systematic Reviews · doi:10.1186/2046-4053-1-33 · Cited by 159
“Inferences should also be limited considering the frequent use of the surrogate outcome, prolactin level, as opposed to patient-important outcomes [25], such as loss of quality of life due to tumor-related and hypogonadal symptoms.”
BackgroundSelf-citationDetermination of prolactin: The macroprolactin problem
Fahie‐Wilson, M. N., & Smith, T. P. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.07.002 · Cited by 167
Aging and sex hormones in males
Decaroli, M. C., & Rochira, V. (2017) · Virulence · doi:10.1080/21505594.2016.1259053 · Cited by 144
Najafabadi, A. H. Z., Zandbergen, I. M., de Vries, F., Broersen, L. H. A., Marle, M. E. V. D. A., Pereira, A. M., Peul, W. C., Dekkers, O. M., van Furth, W. R., & Biermasz, N. R. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz144 · Cited by 145
Drug-induced gynecomastia: an evidence-based review
Deepinder, F., & Braunstein, G. D. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.712109 · Cited by 151
“These levels are higher than most patients with drug-induced gynecomastia, which rarely exceed 100 ng/ml, the exceptions being with risperidone [47].”
BackgroundOptic Nerve Hypoplasia Syndrome: A Review of the Epidemiology and Clinical Associations
Garcia-Filion, P. C., & Borchert, M. (2012) · Current Treatment Options in Neurology · doi:10.1007/s11940-012-0209-2 · Cited by 147
Antipsychotic-Induced Hyperprolactinaemia
Inder, W. J., & Castle, D. (2011) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2011.589044 · Cited by 133
Time for a New Perspective on Prolactin in Metabolism
Macotela, Y., Triebel, J., & Clapp, C. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.01.004 · Cited by 149
Mutant Prolactin Receptor and Familial Hyperprolactinemia
Newey, P. J., Gorvin, C. M., Cleland, S. J., Willberg, C. B., Bridge, M., Azharuddin, M. K., Drummond, R. S., van der Merwe, P. A., Klenerman, P., Bountra, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307557 · Cited by 132
Hyperprolactinemia: pathophysiology and therapeutic approach
Capozzi, A., Scambia, G., Pontecorvi, A., & Lello, S. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1017810 · Cited by 126
“Hyperprolactinemia may be due to medications, for example neuroleptics or antidepressants, or be idiopathic [1,6].”
BackgroundInfluentialProlactin Biology and Laboratory Measurement: An Update on Physiology and Current Analytical Issues.
Saleem, M., Martin, H., & Coates, P. S. (2018) · Europe PMC (PubMed Central) · Cited by 187
Grigg, J., Worsley, R., Thew, C., Gurvich, C., Thomas, N., & Kulkarni, J. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4730-6 · Cited by 145
“Two guidelines (Melmed et al., 2011; Tomova et al., 2016) recommend, when discontinuation is not feasible, to (1) reduce the dose of the PRL-raising agent, (2) switch to an alternative low potency or PRL-sparing agent or (3) add a full or partial dopamine agonist—with varying levels of caution…”
BackgroundMethodInfluentialThe Relationship Between Bone and Reproductive Hormones Beyond Estrogens and Androgens
Mills, E. G., Yang, L., Nielsen, M. F., Kassem, M., Dhillo, W. S., & Comninos, A. N. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab015 · Cited by 119
Samperi, I., Lithgow, K. C., & Karavitaki, N. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122203 · Cited by 160
“Any lesion leading to interruption of the dopaminergic pathways due to compression of the pituitary stalk and portal vessels can lead to hyperprolactinaemia through the “stalk effect” [including pituitary adenomas with the most common cause in this setting being the non-functioning pituitary adenomas (NFA); parasellar…”
BackgroundInfluentialHow to manage osteoporosis before the age of 50.
Rozenberg, S., Bruyère, O., Bergmann, P., Cavalier, E., Gielen, E., Goemaere, S., Kaufman, J. M., Lapauw, B., Laurent, M. R., De Schepper, J., et al. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.05.004 · Cited by 118
“Surgery or radiological treatment is seldom indicated for the treatment of pituitary macroadenoma [113].”
BackgroundGiant prolactinomas: the therapeutic approach
Moraes, A. B., Silva, C. M. D. S., Neto, L. V., & Gadelha, M. R. (2013) · Clinical Endocrinology · doi:10.1111/cen.12242 · Cited by 122
Psychotropic-Induced Hyperprolactinemia: A Clinical Review
Ajmal, A., Joffe, H., & Nachtigall, L. B. (2013) · Psychosomatics · doi:10.1016/j.psym.2013.08.008 · Cited by 132
Auriemma, R. S., Perone, Y., Sarno, A. D., Grasso, L. F. S., Guerra, E., Gasperi, M., Pivonello, R., & Colao, A. A. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3039 · Cited by 116
Gubbi, S., Hannah‐Shmouni, F., Verbalis, J. G., & Koch, C. A. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.101371 · Cited by 121
Molitch, M. E. (2011) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.05.011 · Cited by 114
Metabolic effects of prolactin
Pirchio, R., Graziadio, C., Colao, A., Pivonello, R., & Auriemma, R. S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1015520 · Cited by 139
“PRL levels ≤ 25 mg/L are currently considered normal, whereas the suspicion of prolactinoma arises when PRL exceeds 200 mg/L (3).”
BackgroundInfluentialT2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly
Potorac, I., Pétrossians, P., Daly, A., Alexopoulou, O., Borot, S., Sahnoun-Fathallah, M., Castinetti, F., Devuyst, F., Jaffrain‐Rea, M., Briet, C., et al. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0356 · Cited by 111
An updated view of hypothalamic–vascular–pituitary unit function and plasticity
Tissier, P. L., Campos, P., Lafont, C., Romanò, N., Hodson, D. J., & Mollard, P. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.193 · Cited by 122
Salenave, S., Ancelle, D., Bahougne, T., Raverot, G., Kamenický, P., Bouligand, J., Guiochon‐Mantel, A., Linglart, A., Souchon, P., Nicolino, M. P., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3670 · Cited by 115
“A DA is the first-line treatment of choice for adults with macroprolactinomas (37).”
BackgroundCiresi, A., Amato, M. C., Guarnotta, V., Castro, F. L., & Giordano, C. S. D. S. (2013) · Clinical Endocrinology · doi:10.1111/cen.12204 · Cited by 111
Approach to the Patient With Prolactinoma
Auriemma, R. S., Pirchio, R., Pivonello, C., Garifalos, F., Colao, A., & Pivonello, R. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad174 · Cited by 147
Vilar, L., Abucham, J., Albuquerque, J. L., de Araújo, L. A., Azevedo, M. F., Boguszewski, C. L., Casulari, L. A., Cunha, M. B. C., Czepielewski, M. A., Duarte, F. H. G., et al. (2018) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000032 · Cited by 110
“Nevertheless, according to the guidelines of the Endocrine Society, a single PRL level above the upper limit of normal confirms the diagnosis of hyperprolactinemia, as long as the serum sample was obtained without excessive venipuncture stress (4).”
BackgroundMethodInfluentialFemale infertility of endocrine origin
Weiss, R. V., & Clapauch, R. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000003021 · Cited by 119
“It is recommended that serum prolactin is measured twice before sellar imaging is requested, particularly in women with borderline levels (< 50 ng/mL) (21).”
BackgroundThe MAPK Pathway-Based Drug Therapeutic Targets in Pituitary Adenomas
Lu, M., Ya, W., & Zhan, X. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00330 · Cited by 110
“Dopamine agonists such as bromocriptine (BRC) and cabergoline (CAB) are primary medical therapy drugs for prolactinomas and idiopathic hyperprolactinemia and prolactinomas (66).”
BackgroundPCOS and Hyperprolactinemia: what do we know in 2019?
Delcour, C., Robin, G., Young, J., & Dewailly, D. (2019) · Clinical Medicine Insights Reproductive Health · doi:10.1177/1179558119871921 · Cited by 122
ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy
Luger, A., Broersen, L. H. A., Biermasz, N. R., Biller, B. M. K., Buchfelder, M., Chanson, P., Jørgensen, J. O. L., Keleştimur, F., Llahana, S., Maiter, D. M., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0462 · Cited by 112
Investigation and management of subfertility
Thurston, L., Abbara, A., & Dhillo, W. S. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205579 · Cited by 110
“8 A mildly elevated serum prolactin level (500–1000 mIU/L) can occur due to the stress of venepuncture 9 ; hence, it should be repeated in the first instance (perhaps by a cannulated prolactin if available).”
Temozolomide in the management of dopamine agonist–resistant prolactinomas
Whitelaw, B., Dorota Dworakowska, B., Thomas, N. W., Barazi, S. A., Riordan‐Eva, P., King, A. P., Hampton, T., Landau, D., LIPSCOMB, D. W., Buchanan, C. R., et al. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04373.x · Cited by 96
Challenges and pitfalls in the diagnosis of hyperprolactinemia
Vilar, L., Fleseriu, M., & Bronstein, M. D. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000003002 · Cited by 114
“If drug-induced hyperprolactinemia is confirmed, one should try to switch to an alternative medication (6,19).”
BackgroundInfluentialScott-Brown’s Otorhinolaryngology Head and Neck Surgery
Sathyapalan, T., & Atkin, S. L. (2018) · CRC Press eBooks · doi:10.1201/9780203731031 · Cited by 94
Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges
Wong, A., Eloy, J. A., Couldwell, W. T., & Liu, J. K. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.03.058 · Cited by 89
“Medications are the most common cause of non-tumoral hyperprolactinemia [17].”
BackgroundInfluentialHyperprolactinaemia in male infertility: Clinical case scenarios
Dabbous, Z., & Atkin, S. L. (2017) · Arab Journal of Urology · doi:10.1016/j.aju.2017.10.002 · Cited by 101
“Treatment of hypothyroidism and restoration of normal thyroid-stimulating hormone will lead to normalisation of prolactin levels and does not warrant any additional treatment [27].”
BackgroundInfluentialDoğanşen, S. Ç., Çıkrıkçılı, U., Örük, G., Kutbay, N. Ö., Tanrıkulu, S., Hekimsoy, Z., Hadzalic, A., Görar, S., Omma, T., Mert, M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02202 · Cited by 97
Zhang, F., Zhang, Q., Zhu, J., Yao, B., Ma, C., Qiao, N., He, S., Ye, Z., Wang, Y., Han, R., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00736-5 · Cited by 110
“S5a‒c), which expanded the previous perception that EGFR was highly expressed in ACTH PitNETs.11 Subsequent analysis of EGFR-related pathways defined three groups that showed diverse mechanisms of EGFR activation, including ACTH tumors with USP8 mutation (ACTH_USP8 mutant), ACTH tumors without USP8 mutation (ACTH_ USP…”
BackgroundInfluentialTampourlou, M., Trifanescu, R. A., Paluzzi, A., Ahmed, S. K., & Karavitaki, N. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0087 · Cited by 88
Endocrine evaluation of erectile dysfunction
Sansone, A., Romanelli, F., Gianfrilli, D., & Lenzi, A. (2014) · Endocrine · doi:10.1007/s12020-014-0254-6 · Cited by 94
Ioachimescu, A. G., Fleseriu, M., Hoffman, A. R., Vaughan, T. B., & Katznelson, L. J. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0682 · Cited by 92
Self-citationDe Sousa, S. M. C., Baranoff, J., Rushworth, R. L., Butler, J., Sorbello, J., Vorster, J., Thompson, T., McCormack, A. I., Inder, W. J., & Torpy, D. J. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz076 · Cited by 87
“The risk of DA-induced ICDs is not addressed in hyperprolactinemia guidelines (8,9).”
BackgroundOutcome of prolactinoma after pregnancy and lactation: a study on 73 patients
Domingue, M.-È., Devuyst, F., Alexopoulou, O., Corvilain, B., & Maiter, D. M. (2013) · Clinical Endocrinology · doi:10.1111/cen.12370 · Cited by 87
The role of prolactin in andrology: what is new?
Rastrelli, G., Corona, G., & Maggi, M. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-015-9322-3 · Cited by 94
Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors
Cooper, O. B., Mamelak, A. N., Bannykh, S., Carmichael, J. D., Bonert, V. S., Lim, S. W., Cook‐Wiens, G., & Ben-Shlomo, A. (2013) · Endocrine · doi:10.1007/s12020-013-0093-x · Cited by 84
Update on prolactinomas. Part 2: Treatment and management strategies
Wong, A., Eloy, J. A., Couldwell, W. T., & Liu, J. K. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.03.059 · Cited by 84
“7% of patients with bromocriptine refractory prolactinomas who are switched to cabergoline [12,25,31].”
BackgroundEffect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas
Zhang, D., Way, J. S. A., Zhang, X., Mareninov, S., Bergsneider, M., Wang, M. B., Yong, W. H., & Heaney, A. P. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02461 · Cited by 83
Functioning Pituitary Adenomas – Current Treatment Options and Emerging Medical Therapies
Varlamov, E. V., McCartney, S., & Fleseriu, M. (2019) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2019.15.1.30 · Cited by 99
“Cabergoline is recommended over bromocriptine due to higher potency and effectiveness when compared with bromocriptine.(28) Cabergoline normalises prolactin in 83% versus bromocriptine in 59% of women with hyperprolactinaemic amenorrhea.”
BackgroundInfluentialReproductive function in male patients with type 1 diabetes mellitus
La Vignera, S., Condorelli, R. A., Di Mauro, M., Lo Presti, D., Mongioì, L. M., Russo, G., & Calogero, A. E. (2015) · Andrology · doi:10.1111/andr.12097 · Cited by 82
“…= total testosterone 3 ng/mL or 10.4 nM (Dandona & Rosenberg, 2010), hyperprolactinemia = a level above the upper limit of normal after a single measurement of serum levels (Melmed et al., 2011), hyperestrogenism = >42 pg/mL (Reinsberg et al., 2009), thyroid disorders (V€olzke et al., 2007).”
BackgroundInfluentialUnderstanding the role of dopamine in cancer: past, present and future
Grant, C. E., Flis, A. L., & Ryan, B. M. (2022) · Carcinogenesis · doi:10.1093/carcin/bgac045 · Cited by 92
Medical treatment of male infertility.
Dabaja, A. A., & Schlegel, P. N. (2014) · PubMed Central · doi:10.3978/j.issn.2223-4683.2014.01.06 · Cited by 114
“Patients that fail cabergoline or dose modification are recommended to undergo surgery (27).”
BackgroundMALDI mass spectrometry imaging analysis of pituitary adenomas for near-real-time tumor delineation
Calligaris, D., Feldman, D. R., Norton, I. H., Olubiyi, O. I., Changelian, A. N., Machaidze, R., Vestal, M. L., Laws, E. R., Dunn, I. F., Santagata, S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423101112 · Cited by 81
Freire, C., Koifman, R. J., Sarcinelli, P. D. N., Rosa, A. C. S., Clapauch, R., & Koifman, S. (2013) · International Journal of Hygiene and Environmental Health · doi:10.1016/j.ijheh.2013.07.012 · Cited by 91
Hyperprolactinemia and infertility: new insights
Kaiser, U. B. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64455 · Cited by 83
“mality, and macroadenomas may enlarge during pregnancy if untreated (1, 2).”
Jethwa, P. R., Patel, T. D., Hajart, A. F., Eloy, J. A., Couldwell, W. T., & Liu, J. K. (2015) · World Neurosurgery · doi:10.1016/j.wneu.2015.10.090 · Cited by 79
Subclinical hyperfunctioning pituitary adenomas: The silent tumors
Cooper, O. B., & Melmed, S. K. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2012.01.002 · Cited by 83
Self-citationOstuzzi, G., Bighelli, I., So, R., Furukawa, T. A., & Barbui, C. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.11.010 · Cited by 88
Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
Ludlam, W. H. (2011) · Yearbook of Medicine · doi:10.1016/s0084-3873(11)00353-1 · Cited by 77
Hypothalamic dopamine signalling regulates brown fat thermogenesis
Folgueira, C., Beiroa, D., Porteiro, B., Duquenne, M., Puighermanal, E., Fondevila, M. F., Barja-Fernández, S., Gallego, R., Hernández-Bautista, R., Castelao, C., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0099-7 · Cited by 86
Montejo, Á. L., Arango, C., Bernardo, M., Carrasco, J. L., Crespo-Facorro, B., Cruz, J. J., Del Pino-Montes, J., García-Escudero, M. A., García-Rizo, C., González-Pinto, A., et al. (2017) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.02.003 · Cited by 75
Tsukamoto, T., & Miki, Y. (2023) · Japanese Journal of Radiology · doi:10.1007/s11604-023-01400-7 · Cited by 77
“Bone loss occurs secondary to sex steroid depletion via hyperprolactinemia [30].”
BackgroundUPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS
Lim, C. T., & Korbonits, M. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0034 · Cited by 86
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice
Brandi, M. L., Pieterman, C. R. C., English, K. A., Lines, K. E., Shariq, O. A., Marini, F., Cuny, T., Lewis, M. A., Stratakis, C. A., Perrier, N. D., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00119-6 · Cited by 110
Self-citationMetabolic effects of prolactin and the role of dopamine agonists: A review
Kirsch, P. M., Kunadia, J., Shah, S., & Agrawal, N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1002320 · Cited by 88
“Exercise • Mechanism is not well understood • PRL may be elevated for about 30 minutes after high intensity exercise (13, 30) Polycystic Ovarian Syndrome • Mechanism is not well understood • Elevated PRL is often seen in PCOS (31, 32)”
BackgroundInfluentialPrevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems
Lee, D., Oh, Y.-K., Yoon, B.-K., & Choi, D. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.12.010 · Cited by 74
Glezer, A., & Bronstein, M. D. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.11.003 · Cited by 104
Management of pituitary tumors in pregnancy
Bronstein, M. D., Paraíba, D. B., & Jallad, R. S. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.38 · Cited by 76
Metadata
- Authors
- Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Universidade de Santiago de Compostela (ES)
- VA Palo Alto Health Care System (US)
- New York University (US)
- University of Iowa (US)
- Churchill Hospital (GB)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-02
- Volume
- 96
- Issue
- 2
- Pages
- 273-288
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2019055295
- Semantic Scholar
- 43454263bc46394124a75b19ce2b73452ff5e993
- Cited by
- 1,844
- References
- 141
- Citations by year
- 2026: 133 · 2025: 125 · 2024: 141 · 2023: 150 · 2022: 186 · 2021: 170 · 2020: 138 · 2019: 148 · 2018: 103 · 2017: 107 · 2016: 102 · 2015: 97 · 2014: 76 · 2013: 66 · 2012: 71
- FWCI
- 61.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Funders
- U.S. Department of Defense
- Eli Lilly and Company
- Pfizer
- Teva Pharmaceutical Industries
- European Society of Endocrinology
- Novo Nordisk
- Ipsen
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- hyperprolactinemia, prolactinoma, drug-induced hyperprolactinemia, prolactinoma treatment, pregnancy
- MeSH terms
- Adult, Female, Humans, Hyperprolactinemia, Pituitary Neoplasms, Pregnancy, Prolactinoma, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.